BCIQ Profiles

Company Profile Report
0617 Lenz Versant EMB 8a Thu
BioCentury & Getty Images

Emerging Company Profile

Lenz: focused on an eye drop for age-related farsightedness

Emerging Company Profile: With Versant, RA Capital-backed $47M series A, Lenz eyes pivotal study for presbyopia program

With a Versant and RA Capital-backed $47 million series A round, Lenz eyes pivotal study for presbyopia program. 

Jun 17, 2021 | 3:08 PM GMT

Lenz is well-financed to begin

Read the full 649 word article

How to gain access

Continue reading with a
two-week free trial.